VivoSeq
Immunology

Lupus

17

Pipeline Programs↗

8

Active Trials↗

14

Companies Involved↗

Lupus is an emerging landscape with 17 programs across 14 companies. The most active players are UCB, GSK, Roche. 2 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

11/100

Mech. Concentration

11/100

Completion Rate

69/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

UCB logo

UCB

1 program

Phase 1GSK logo

GSK

2 programs

Phase 2Roche logo

Roche

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2Takeda logo

Takeda

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

14programs
Small molecule857%
Monoclonal antibody536%
Protein / enzyme17%

Modality classified for 82% of 17 pipeline programs.

Analysis

Trial Status

21

clinical trials

Completed9 · 43%
Active, not recruiting4 · 19%
Recruiting3 · 14%
Terminated2 · 10%
Withdrawn2 · 10%
Not yet recruiting1 · 5%

Clinical Trials

Trial Activity

21 trials

Trial of Belimumab in Early Lupus
Recruiting·NNorthwell Health·Phase 4·NCT03543839·30 enrolled
A Phase II Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Mosunetuzumab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Recruiting·Roche logoRoche·Phase 2·NCT07598396·30 enrolled
GLOW-1: Efgartigimod in Systemic Lupus
Recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT04170543·450 enrolled
MUSE: Anifrolumab in Moderate SLE
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT06800008·460 enrolled
TULIP-SC: Anifrolumab SC in SLE
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT04504032·352 enrolled
ATLAS: Efgartigimod in Myasthenia Gravis Extension
Active, not recruiting·Argenx logoArgenx·Phase 3·NCT04818242·300 enrolled
GLOW-2: Efgartigimod in CIDP
Active, not recruiting·Argenx logoArgenx·Phase 3·NCT04818475·240 enrolled
ROSY-S: Rollover Study for Participants Who Have Completed a Previous Study With Anifrolumab (Saphnelo) and Are Assessed by the Investigator to Clinically Benefit From Continued Treatment
Not yet recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT07691970·1,072 enrolled
Triptorelin for Ovary Protection in Childhood Onset Lupus
Completed·—·Phase 2·NCT00124514·31 enrolled
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
Completed·GSK logoGSK·Phase 3·NCT00724867·268 enrolled
Aurinia Renal Response in Active Lupus With Voclosporin
Completed·Aurinia Pharmaceuticals logoAurinia Pharmaceuticals·Phase 3·NCT03021499·358 enrolled
A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
Completed·GSK logoGSK·Phase 3·NCT00712933·738 enrolled
Lupus and Observance
Completed·UUniversity Hospital Center of Martinique·N/A·NCT03019926·200 enrolled
Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations
Completed·HHospital Universitari Vall d'Hebron Research Institute·Phase 4·NCT01112215·240 enrolled
A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT00657189·87 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)